{"id":136920,"date":"2022-11-16T09:08:53","date_gmt":"2022-11-16T14:08:53","guid":{"rendered":"https:\/\/44.250.171.167\/?p=136920"},"modified":"2022-11-16T09:08:55","modified_gmt":"2022-11-16T14:08:55","slug":"biocon-limited-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/biocon-limited-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Biocon Limited Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Biocon Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/BIOCON\/\">BIOCON<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:23:49] Prakash Agarwal of Axis Capital asked about the mezzanine funding and when is it expected to reverse and the reason for funding delay. Siddharth Mittal CEO replied that BIOCON is in discussions with various private equity investors. Within the next few months, BIOCON expects to retire the short term debt to fund the payout immediately and also raising fund from private equity.<\/li>\n<\/ul>\n<ul>\n<li>[00:24:58] Prakash Agarwal of Axis Capital also enquired about an update on Beva and Aspart approval timelines. Shreehas Tambe Deputy CEO replied that at this stage there is no indication on the timeline, but BIOCON is engaging with them and see how it can be expedited.<\/li>\n<\/ul>\n<ul>\n<li>[00:28:25] Shyam Srinivasan with Goldman Sachs enquired about Biocon Biologics; Glargine market shares reaching on NRx about 14%, if BIOCON is on track for high teens market share. Shreehas Tambe Deputy CEO said it\u2019s trending in the right direction towards the mid to high teens market share in the US.<\/li>\n<\/ul>\n<ul>\n<li>[00:30:31] Shyam Srinivasan with Goldman Sachs asked about some concerns about biosimilar pricing and BIOCON\u2019s expectation on pricing. Shreehas Tambe Deputy CEO answered most customers are looking at stability of supply. BIOCON believes there is pricing sanity overall and believe that this is likely to be a reflection of the biosimilars marketplace in the near term.<\/li>\n<\/ul>\n<ul>\n<li>[00:32:58] Shyam Srinivasan with Goldman Sachs asked about API and formulation trends for the generics business. Siddharth Mittal CEO replied BIOCON should continue to see some growth coming in the API business as newer capacities are there both from brownfield and greenfield in the coming quarters. Overall, 2H23 is expected to have high single-digit growth vs. 2H22.<\/li>\n<\/ul>\n<ul>\n<li>[00:39:30] Neha Manpuria from Bank of America enquired how the emerging markets have been trending QonQ, if growth is seen in the ex-regulated market business on biosimilar. Shreehas Tambe Deputy CEO said the emerging markets have been doing well for BIOCON on all the three franchise.<\/li>\n<\/ul>\n<ul>\n<li>[00:43:45] Damayanti Kerai from HSBC asked about the split in terms of biosimilar sales between advance and emerging market. M.B. Chinappa CFO said it\u2019s under 60% in advanced markets and just above 40% for Emerging Markets.<\/li>\n<\/ul>\n<ul>\n<li>[00:48:42] Harith Ahamed with Spark Capital asked about facilities related to the decline in tangible CWIP in the consolidated balance sheet by around INR1,300 crores. M.B. Chinappa CFO said it pertains to capitalization of one of the drug substance facilities that has gone online in the quarter of July to Sept.<\/li>\n<\/ul>\n<ul>\n<li>[00:50:17] Masira Vasanwala of FSSA Investment Managers asked if there is any collateral or cash flow against which mezzanine finance is secured. \u00a0Siddharth Mittal CEO replied that it would be secured debt against the underlying assets of Biocon Limited. So there will be no other collateral.<\/li>\n<\/ul>\n<ul>\n<li>[00:53:00] Sameer Baisiwala from Morgan Stanley asked about the market share outlook for Glargine. Shreehas Tambe Deputy CEO said that for 2023, for Glargine, BIOCON will retain the current customers that it has contracted with and will stay with those markets. BIOCON will trend towards the guided mid to high teens.<\/li>\n<\/ul>\n<ul>\n<li>[00:59:01] Dhruv Singhal asked about the potential timeline for IPO biologics and if a demerger of Syngene and Biologics is expected. Siddharth Mittal CEO answered that it\u2019s a bit premature, but it won\u2019t happen before the next 12 months or so.<\/li>\n<\/ul>\n<ul>\n<li>[01:04:13] Dinesh Mahajan asked about BIOCON\u2019s market share in India of insulin glargine and if it coming under price control in India impact margins. Susheel Umesh CCO replied that glargine in India, is doing extremely well vs. last year, growing at more than 25% in a market that&#8217;s growing at about 3%.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Q&amp;A Highlights: [00:23:49] Prakash Agarwal of Axis Capital asked about the mezzanine funding and when is it expected to reverse and the reason for funding delay. Siddharth Mittal CEO replied that BIOCON is in discussions with various private equity investors. Within the next few months, [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Biocon Limited Q2 FY23 Earnings Conference Call Insights #BIOCON #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,1115],"class_list":["post-136920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":137052,"url":"https:\/\/alphastreet.com\/india\/biocon-limited-biocon-q2-fy23-earnings-concall-transcript\/","url_meta":{"origin":136920,"position":0},"title":"Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"November 14, 2022","format":false,"excerpt":"Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar Shaw -- Executive Chairperson Siddharth Mittal -- Chief Executive Officer & Managing Director Shreehas P Tambe -- Deputy Chief Executive Officer Matthew Erick -- Chief Commercial Officer, Advanced\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172340,"url":"https:\/\/alphastreet.com\/india\/biocon-q2-fy26-earnings-results\/","url_meta":{"origin":136920,"position":1},"title":"Biocon Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 12, 2025","format":false,"excerpt":"Biocon Ltd, a prominent biotechnology company engaged in manufacturing biotechnology products and research services, reported extraordinary financial results for Q2FY26. Financial Highlights: Revenues grew 19.67% year-on-year to \u20b94,296 crore from \u20b93,590 crore. Total expenses increased 18.42% to \u20b94,205 crore from \u20b93,551 crore. Consolidated net profit skyrocketed 392.59% to \u20b9133 crore\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/BIO.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":141647,"url":"https:\/\/alphastreet.com\/india\/biocon-ltd-nse-biocon-ltd-q3-fy23-results-out-total-income-rise-35-yoy\/","url_meta":{"origin":136920,"position":2},"title":"Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY","author":"Divyansh_Kasana","date":"February 14, 2023","format":false,"excerpt":"Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by Kiran Mazumdar-Shaw and is now one of the largest biopharmaceutical companies in India. Biocon is primarily engaged in the production of biosimilars, generic biologics, and research-based pharmaceuticals. It also has\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/5ae0e933-d8c2-4fc6-912a-65a97b6504cf.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170318,"url":"https:\/\/alphastreet.com\/india\/biocon-q1-fy26-earnings-results\/","url_meta":{"origin":136920,"position":3},"title":"Biocon Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 19, 2025","format":false,"excerpt":"Biocon Limited, engaged in the manufacture of biotechnology products and research services, reported its Q1 FY26 Earnings results. Q1 FY26 Earnings Results Revenue: \u20b93,942 crore, up 14.83% year-on-year (YoY) from \u20b93,433 crore in Q1 FY25. Total Expenses: \u20b93,925 crore, up 13.67% YoY from \u20b93,453 crore. Consolidated Net Profit (PAT): \u20b989\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"BIOCON Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/BIOCON.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147229,"url":"https:\/\/alphastreet.com\/india\/alphagraph-biocon-limited-nse-biocon-q4fy23-results-out-total-income-rises-58-yoy\/","url_meta":{"origin":136920,"position":4},"title":"Alphagraph | Biocon Limited (NSE: BIOCON): Q4FY23 Results Out; Total Income rises 58% YoY.","author":"Divyansh_Kasana","date":"May 24, 2023","format":false,"excerpt":"Biocon is a prominent player in the biotechnology industry, specializing in the manufacturing of biotechnology products and offering research services. With a strong focus on innovation and scientific expertise, Biocon has made significant contributions to the field of biotechnology. The company's diverse portfolio encompasses a range of biopharmaceuticals, including biosimilars,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/213490c7-5a56-4586-825e-f4dfdab0cb23-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":141913,"url":"https:\/\/alphastreet.com\/india\/biocon-limited-biocon-q3-fy23-earnings-concall-transcript\/","url_meta":{"origin":136920,"position":5},"title":"Biocon Limited (BIOCON) Q3 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"February 15, 2023","format":false,"excerpt":"Biocon Limited (NSE:BIOCON) Q3 FY23 Earnings Concall dated Feb. 15, 2023. Corporate Participants: Saurabh Paliwal\u00a0--\u00a0Head - Investor Relations Kiran Mazumdar Shaw\u00a0--\u00a0Biocon Ltd. Shreehas P. Tambe\u00a0--\u00a0CEO & MD, Biocon Biologics Ltd. Matthew Erick\u00a0--\u00a0Chief Commercial Officer - Advanced Markets Siddharth Mittal\u00a0--\u00a0CEO & Managing Director Chinappa M.B.\u00a0--\u00a0Chief Financial Officer, Biocon Biologics Indranil Sen\u00a0--\u00a0Chief\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=136920"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/136920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=136920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=136920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=136920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}